BOULDER, Colo., and SAN FRANCISCO, Feb. 12, 2013 /PRNewswire/ -- BiOptix in conjunction with Molecular Med TRI-CON 2013 will officially announce the expansion of the BiOptix Innovators Program, a unique-to-the-industry "try before you buy" instrument demo program that encourages researchers and institutions to become acquainted with the new BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology.
During the event, Ken Wilczek, Vice President of Sales and Marketing for BiOptix remarked: "We are actively seeking and qualifying researchers and institutions who would like to experience a new way of evaluating and purchasing an SPR instrument." "Through the marriage of excellent customer service and world-class technology, BiOptix aims to simplify the SPR instrument evaluation process, building a true partnership with scientific researchers to demonstrate the capabilities of the 404pi, a 21st century benchmark for new and innovative label-free SPR instrumentation." "Quite simply, this is not your father's SPR instrumentthe BiOptix 404pi will change how you think and work with SPR." continued Wilczek.
Additional details about the BiOptix Innovators Program, including how you or your institution can request a demo of the BiOptix 404pi can be found at: http://www.bioptix.com/products/innovators-program or by contacting BiOptix at: 303-545-5550 x 125.
In addition to Molecular Med TRI-CON 2013, BiOptix will be highlighting the 404pi at the following events during the first half of 2013:
- PepTalk 2013 The Protein Science Week
- BioPhysical Society 57th Annual Meeting
- IBC's Biopharmaceutical Development & Production Week
- US HUPO
- AACR The American Association for Cancer Research
- 9th Annual Pegs The Essential Protein Engineering Summit
- 2013 Merck Technology Symposia
- TIDES 2013 Oligonucleotide and Peptide Research, Technology and Product Development
- 2013 Bristol-Myers Squibb Vendor & Technology Symposia
Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interactionwith high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com
SOURCE BiOptix Diagnostics Corporation